Leukotrienes are powerful inflammatory mediators that act through leukotriene receptors in cell membranes and can cause bronchospasm, increase airway hyperresponsiveness, increase mucus secretion, aggravate mucosal edema, promote airway smooth muscle proliferation, and play an important role in the pathogenesis of asthma. Clinical studies have found significantly elevated leukotriene levels in dysmenorrheic patients and menstruating asthmatics. Leukotriene receptor antagonists, such as montelukast (cisplatin), have a high affinity for leukotriene receptors and can effectively inhibit the effects of leukotrienes. It can improve airway function and improve symptoms and quality of life in patients with dysmenorrhea and asthma. Although glucocorticoid is one of the most powerful anti-inflammatory drugs available, it does not inhibit all inflammatory responses in asthma, and some menstrual asthma cannot be controlled by corticosteroids. Therefore, the application of inhaled corticosteroids plus leukotriene modifiers in the treatment of dysmenorrhea and menstrual asthma can improve asthma control.